Skip to content
type1.science

Selective JAK inhibitors (abrocitinib / ritlecitinib)

Pfizer (repurposed agents)

A TrialNet phase-2 study testing two newer oral JAK-pathway drugs - abrocitinib and ritlecitinib - in recent-onset stage-3 T1D. This is distinct from baricitinib: different JAK selectivity, NIH/TrialNet sponsor, and no published T1D efficacy result yet.

On the horizonEarly evidenceimmunotherapyjak-inhibitororalbeta-cell-preservation

The scorecard

Delay of onset25

No published T1D efficacy result yet; JAKPOT tests C-peptide preservation at new-onset, not presymptomatic onset delay.[1]

Durability20

Durability unknown until the active trial reports treatment and follow-up outcomes.[1]

Safety40

Oral delivery is attractive, but JAK-class safety warnings matter strongly for long-term use in young T1D populations.[2]

Stage breadth25

Current evidence program is recent-onset stage 3 only, ages 12-35.[1]

Access & cost15

Both agents are approved for other immune conditions, but T1D use remains investigational.[1]

Editor’s take

Baricitinib made oral JAK inhibition credible in T1D; JAKPOT asks whether more selective JAK-pathway drugs can preserve C-peptide with a better risk-benefit profile. It is promising enough to track, but still pre-result.

The full picture

Why this is separate from baricitinib

Baricitinib is already covered because BANDIT published a positive new-onset phase-2 result. JAKPOT is a separate TrialNet test of abrocitinib and ritlecitinib, two different oral JAK-pathway drugs, in the same broad idea: preserve residual beta-cell function after diagnosis.1

No T1D efficacy result is published yet. This is pipeline coverage, not a positive-result record.

References

  1. National Library of Medicine. JAK inhibitors to preserve C-peptide production in new-onset T1D. ClinicalTrials.gov NCT05743244. https://clinicaltrials.gov/study/NCT05743244 ↩

Coming soon

ETA · Phase 2 active not recruiting; completion estimated 2027

  • →JAKPOT T1D phase-2 results · completion estimated 2027

Sources

  1. [1]Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes · registry · 2026-05-29 — TrialNet / NIDDK phase 2; active not recruiting; estimated n=78; ages 12-35; abrocitinib vs ritlecitinib vs placebo.
  2. [2]CIBINQO (abrocitinib) prescribing information · regulatory · 2022-01-14 — FDA label for atopic dermatitis; no T1D indication.